A new review in Genes & Diseases describes how DNA-based technologies are moving medicine toward a future in which disease is detected and prevented before symptoms emerge. Rather than relying primarily on treatments after illness has developed, researchers are increasingly using genetic information to identify biological risks early, monitor molecular changes over time, and intervene with greater precision. The review, titled “Molecular mastery: Harnessing DNA technology for disease prevention,” examines how gene editing, epigenetics, RNA technologies, genome sequencing, synthetic biology, and artificial intelligence are converging to transform preventive healthcare.
At the center of this transformation is CRISPR-Cas9, a genome-editing system adapted from a bacterial defense mechanism. CRISPR uses a guide RNA to direct the Cas9 enzyme to a selected DNA sequence, where the enzyme makes a targeted cut. Cellular repair mechanisms can then be used to disable a harmful gene, correct a disease-causing sequence, or insert a functional genetic instruction. This approach has already moved beyond laboratory experiments, with clinical applications demonstrating its potential in inherited blood disorders such as sickle cell disease. In the longer term, similar strategies could be developed to prevent or reduce the impact of other genetic conditions, including cystic fibrosis and selected forms of cancer.
The review emphasizes that gene editing is not a single technology but a rapidly expanding family of molecular tools. Newer systems, including base editors and prime editors, are designed to make more precise changes while reducing the need to cut both strands of the DNA molecule. Base editors can chemically convert one DNA letter into another without creating a conventional double-strand break, while prime editing can install certain substitutions, insertions, or deletions using a programmable template. These advances could improve safety, although scientists still need to control unintended edits, immune reactions, and the delivery of editing components to the correct tissues.
A major distinction in clinical genome editing is whether the intervention affects reproductive cells or only the treated individual. Somatic cell genome editing targets non-reproductive tissues, such as blood stem cells or liver cells, and its genetic changes are not expected to pass to future generations. This makes somatic editing a more practical and ethically acceptable route for medicine. By contrast, heritable or germline editing would introduce changes into embryos or reproductive cells, allowing them to be inherited by descendants. The review presents somatic approaches as a promising path for treating genetic disease while avoiding many of the ethical concerns associated with permanent changes to the human germline.
DNA sequence, however, is only one layer of biological information. The authors also highlight epigenetic regulation, a system that controls gene activity without changing the underlying genetic code. Chemical marks such as DNA methylation, together with modifications to histone proteins around which DNA is packaged, can determine whether genes are activated or silenced. Diet, pollution, smoking, stress, aging, and other environmental influences can affect these regulatory patterns. Because many epigenetic changes are reversible, researchers are investigating whether they can be modified to reduce the risk of cancer, metabolic disease, and other chronic conditions. Epigenetic signatures may also serve as early biomarkers, revealing abnormal cellular processes before clinical symptoms become apparent.
RNA-based technologies add another layer to this preventive toolkit. Messenger RNA, or mRNA, carries genetic instructions from DNA to cellular ribosomes, where proteins are produced. By delivering carefully designed mRNA molecules, scientists can temporarily instruct cells to make a therapeutic protein, stimulate an immune response, or regulate a disease-related pathway without permanently altering the genome. The success of mRNA vaccine platforms has accelerated interest in applications beyond infectious disease, including personalized cancer vaccines, treatments for rare genetic disorders, and strategies that could intercept disease progression at an early stage.
Next-generation sequencing is helping make such prevention strategies more individualized. Unlike older sequencing methods, which examined relatively small portions of DNA, modern platforms can analyze entire genomes or comprehensive panels of disease-associated genes at increasing speed and decreasing cost. Sequencing can identify inherited variants, somatic mutations acquired during life, and molecular patterns associated with elevated disease risk. When combined with family history, medical records, and environmental information, these data can support risk assessment and guide surveillance or preventive treatment. Yet a genetic variant is not automatically a diagnosis: its significance may depend on penetrance, other genes, lifestyle, and the quality of available clinical evidence.
Artificial intelligence is expected to expand the usefulness of these vast datasets. Machine-learning systems can examine relationships among genetic variants, gene-expression profiles, epigenetic marks, imaging results, and clinical outcomes that would be difficult to detect manually. AI-assisted genome analysis may help prioritize potentially harmful mutations, predict how a patient will respond to a therapy, and identify molecular signals that precede disease. Synthetic biology could complement these efforts by enabling researchers to design biological circuits, engineered cells, or molecular sensors that respond to specific disease signals. Together, these technologies are laying the foundation for more predictive and personalized forms of medicine.
The review also makes clear that technological promise does not eliminate practical and ethical barriers. Gene-editing systems must reach the correct cells while avoiding unintended tissues, and researchers must establish reliable methods for measuring off-target effects over long periods. Genetic screening can produce uncertain findings, raise questions about privacy, and expose disparities when advanced tools are available only to wealthier populations. Preventive interventions must therefore be evaluated not only for molecular precision but also for clinical benefit, affordability, informed consent, and equitable access. The authors argue that responsible oversight will be essential as DNA technologies move from research laboratories into routine healthcare.
Taken together, the advances described in the review signal a shift from reactive medicine toward molecular prevention. CRISPR-based editing may correct harmful mutations, epigenetic tools may reveal or modify reversible disease risks, RNA platforms may regulate biological processes temporarily, and sequencing combined with AI may identify danger before it becomes visible. These approaches remain under development, and many will require years of clinical testing. Even so, the emerging framework is changing the central question of healthcare—from how to treat established disease to how genetic and molecular knowledge can be used to prevent it in the first place.
Subject of Research: DNA-based technologies for disease prevention, including CRISPR-Cas9 gene editing, epigenetic regulation, RNA therapies, somatic genome editing, next-generation sequencing, synthetic biology, and AI-driven genomic analysis.
Article Title: Molecular mastery: Harnessing DNA technology for disease prevention
Web References: https://doi.org/10.1016/j.gendis.2025.101976
References: Giri Rajasekhar Dornadula, Ramakrishna Chilakala, Sadak Basha Shaik, Pramod Kumar Meriga, Likhitha Chintha, Yeshwanth Gurugari, Kranthi Kumar D, Sameena Fatima Shaik, Sun Hee Cheong, “Molecular mastery: Harnessing DNA technology for disease prevention,” Genes & Diseases, Volume 13, Issue 4, 2026, Article 101976. DOI: 10.1016/j.gendis.2025.101976
Image Credits: Genes & Diseases
Keywords: DNA technology, disease prevention, CRISPR-Cas9, gene editing, epigenetics, RNA therapies, mRNA, somatic genome editing, next-generation sequencing, synthetic biology, artificial intelligence, personalized medicine
